Porwancher R
Department of Medicine, St. Francis Medical Center, Trenton, NJ 08629, USA.
J Infect Dis. 1999 Apr;179(4):1021-4. doi: 10.1086/314651.
A two-step approach for diagnosis of Lyme disease, consisting of an initial EIA followed by a confirmatory Western immunoblot, has been advised by the Centers for Disease Control and Prevention (CDC). However, these criteria do not examine the influence of the prior probability of Lyme disease in a given patient on the predictive value of the tests. By using Bayesian analysis, a mathematical algorithm is proposed that computes the probability that a given patient's Western blot result represents Lyme disease. Assuming prior probabilities of early Lyme disease of 1%-10%, the current CDC minimum criteria for IgM immunoblot interpretation yield posttest probabilities of 4%-32%. The value of the two-step approach for diagnosis of early Lyme disease may be limited in populations at lower risk of disease or when patients present with atypical signs and symptoms.
美国疾病控制与预防中心(CDC)建议采用两步法诊断莱姆病,即先进行酶免疫测定(EIA),随后进行确证性的免疫印迹法检测。然而,这些标准并未考量特定患者中莱姆病的先验概率对检测预测价值的影响。通过贝叶斯分析,提出了一种数学算法,用于计算给定患者免疫印迹结果代表莱姆病的概率。假设早期莱姆病的先验概率为1%-10%,当前CDC对IgM免疫印迹解读的最低标准得出的检测后概率为4%-32%。对于疾病风险较低的人群或出现非典型体征和症状的患者,两步法诊断早期莱姆病的价值可能有限。